Related Experiment Video
Updated: Jun 19, 2026

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity (AIDN): A Translational Neuroscience Approach
Published on: June 11, 2017
Proposals for model-based paediatric medicinal development within the current European Union regulatory framework
Efthymios Manolis1, Gérard Pons
1Scientific Advice and Orphan Drugs, European Medicines Agency, London, UK. efthymios.manolis@emea.europa.eu
Insights
Modelling and simulation (M&S) offers advanced techniques for drug development in children, addressing ethical and regulatory demands. Optimizing M&S integration in regulatory processes is crucial for efficient paediatric medicine development.
Area of Science:
- Pharmacology
- Regulatory Science
- Paediatric Medicine
Background:
- New European Union (EU) regulations mandate paediatric studies, increasing the need for efficient drug development in children.
- Ethical considerations require minimizing the burden of clinical trials on paediatric populations.
- Modelling and simulation (M&S) presents a valuable approach to overcome challenges in paediatric drug development.
Purpose of the Study:
- To explore the regulatory framework for M&S in paediatric medicinal development.
- To propose strategies for model-based paediatric drug development.
- To foster discussion among stakeholders on the optimal use of M&S in this field.
Main Methods:
- Review of the regulatory landscape for M&S in paediatric drug development.
- Analysis of the utility of M&S in addressing sparse data and predicting pharmacokinetics/pharmacodynamics (PK/PD).
- Extrapolation of data from adult to paediatric populations and interpolation between paediatric age subsets.
Main Results:
- M&S enables quantitative analysis of sparse data, characterization of PK/PD, and extrapolation/interpolation of drug effects.
- Industry, academia, and regulators acknowledge the benefits of M&S in paediatric drug development.
- Current integration of M&S into EU regulatory decision-making is limited, with expertise concentrated in specific sectors.
Conclusions:
- M&S is a vital tool for optimizing paediatric drug safety and efficacy assessment.
- Enhanced integration of M&S into regulatory frameworks is necessary for efficient paediatric medicine development.
- Open dialogue between industry, academia, paediatricians, and regulators is essential for advancing model-based paediatric drug development.
Abstract:
The new paediatric European Union (EU) regulation and the consequent demand for paediatric studies on one hand and the ethical need for minimizing the burden of studies in children on the other hand necessitate optimal techniques in the assessment of safety/efficacy and use of drugs in children. Modelling and simulation (M&S) is one way to circumvent some difficulties in developing medicinal products in children. M&S allows the quantitative use of sparse sampling, characterization and prediction of pharmacokinetics/pharmacodynamics (PK/PD), extrapolation from adults to children, interpolation between paediatric age subsets, optimal use of scientific literature and in vitro/preclinical data. Together, industry, academia and regulators recognize the usefulness of modelling and simulation in this setting. However, even if M&S is an emerging science, its integration in the EU regulatory decision making is for the time being deficient and M&S expertise is concentrated in big pharmaceutical companies and academic institutions. The European Medicines Agency, acknowledging all the above conditions, organized and hosted a Workshop on Modelling in Paediatric Medicines. The article presents the personal views of the authors on the issues presented and discussed in the workshop.We attempt to identify the regulatory framework for the use of M&S in paediatric medicinal development and to make proposals for model-based paediatric medicinal development. The objective is to open the discussion between industry, academia, paediatricians and regulators on the optimal use of M&S in paediatric medicinal development.
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Preclinical Development: Overview
Drug Regulation
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacodynamic Models: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment